New Tool Can Help Improve Health Equity in Cancer Centers : Oncology Times
An abstract is unavailable.
Related Articles
Understanding what it is like to experience pain as you… : PAIN
s. We combined the strengths of arts-based methods, translating themes into poems in a range of languages. We screened 7471 titles, 464 abstracts, and 302…
Trump 2016: A look back at the 45th president’s impact on oncology – The Cancer Letter
As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of…
Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma—Less Is More
Current up-front therapeutic approaches for classic Hodgkin lymphoma (cHL) in children and young adults aim to reduce treatment intensity to minimize long-term treatment-related morbidity. This…
Amyloidosis Sessions: Highlights from ASH 2024 | VJHemOnc
Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematology and Hematological Oncology (VJHemOnc). This exclusive session features experts Vaishali Sanchorawala…
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin…
Decoding cost-effectiveness of PNH therapies
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Key PointsNaratuximab emtansine has strong antitumor activity even in models with poor outcome genetic lesions or R-CHOP resistance.PI3Kδ activation, IL-6
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…